Actively Recruiting
Evaluating Oral Azenosertib ZN-c3 in Women with Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Led by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Updated on 2026-10-30
310
Participants Needed
89
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of azenosertib ZN-c3, an oral selective WEE1 inhibitor, in women with platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. This Phase 2 study focuses on patients whose tumors express Cyclin E1 protein, identified through a specialized assay. The study includes multiple parts, with Part 2 specifically enrolling Cyclin E1 positive patients to better understand the drugs impact in this subgroup. Participants receive azenosertib orally, following an intermittent dosing schedule of 400 mg once daily for 5 days, then 2 days off. Different dosing arms exist, including a 300 mg dose, all administered under careful monitoring. The study is randomized and open-label, with several parts completed and Part 2c actively enrolling. The treatment period and follow-up extend for up to approximately 12 months to assess various outcomes. During the study, participants undergo tumor testing, disease evaluation by standard imaging criteria RECIST v1.1, and monitoring of blood markers such as CA-125. Researchers track response rates, duration of response, progression-free survival, clinical benefit, and adverse events. Regular assessments ensure safety and treatment adherence. The total participation duration encompasses treatment and follow-up phases, with outcomes measured up to about one year after the last participant enrolls.
CONDITIONS
Brief Title
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Research Team
P
Project Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here